Next Generation

NCR Voyix Delivers Flexible, Future-Forward Next Generation Self-Checkout Solution for Retailers and Shoppers

Retrieved on: 
Sunday, January 14, 2024
Retail, Data Management, Technology, Finance, Fintech, Banking, Professional Services, Convenience Store, Discount, Variety, Electronic Commerce, Restaurant, Bar, Supermarket, Specialty, Payments, Software, Data Analytics, Next Generation, NRF, API, National Retail Federation, Software as a service, Intelligence, Javits Center, FC Kramatorsk, Investment, RFID, Online shopping

The NCR Voyix Next Generation Self-Checkout Solution is a significant evolution in the checkout experience for retailers and shoppers alike.

Key Points: 
  • The NCR Voyix Next Generation Self-Checkout Solution is a significant evolution in the checkout experience for retailers and shoppers alike.
  • NCR Voyix Insights , available through the NCR Voyix Commerce Platform, provides actionable, proactive and predictive insights in real time.
  • The NCR Voyix Next Generation Self-Checkout Solution accelerates the arrival of frictionless hybrid stores with various modalities of checkout, allowing stores to pivot quickly between assisted and self-checkout lanes or cash and cashless lanes.
  • The NCR Voyix Next Generation Self-Checkout Solution is underpinned by three key market-driven design principles of speed, intelligence and innovation.

UPDATE: Canadians search for hometown friends, heroes and healing in new TVO Original YEARBOOK

Retrieved on: 
Wednesday, January 10, 2024
ASD, Music, Next Generation, Life, Autism spectrum, Social, Learning, Degrassi, Hearing, Human, Racism, Emotion, Politics, Content, Entertainment

Narrated by Paula Brancati (Degrassi: The Next Generation), the six-part documentary series premieres Tuesday, January 16 at 9:00 p.m.

Key Points: 
  • Narrated by Paula Brancati (Degrassi: The Next Generation), the six-part documentary series premieres Tuesday, January 16 at 9:00 p.m.
  • “Yearbook opens a window into powerful and relatable stories that will resonate with many in Ontario and beyond,” says John Ferri, VP of Programming and Content at TVO.
  • YEARBOOK also includes interviews with social workers, counsellors, therapists, and other experts who provide analysis of the circumstances experienced by each subject as they navigate their journey.
  • Stream all six episodes of TVO Original Yearbook on TVO.org , YouTube and your preferred smart TV service.

Leading New York Trial Boutique Led by Marc L. Mukasey Rebrands as Mukasey Young, Naming Torrey Young as Name Partner

Retrieved on: 
Wednesday, January 10, 2024
Legal, Professional Services, LLP, Freedom, CFTC, Government, Michael Mukasey, Next Generation, False Claims Act, Pharmaceutical industry

Approaching its fifth anniversary, leading New York trial boutique Mukasey Frenchman LLP has been renamed Mukasey Young LLP .

Key Points: 
  • Approaching its fifth anniversary, leading New York trial boutique Mukasey Frenchman LLP has been renamed Mukasey Young LLP .
  • The change reflects the departure of co-founder Robert S. Frenchman and a new leadership role for Torrey K. Young as a name partner.
  • View the full release here: https://www.businesswire.com/news/home/20240110388085/en/
    Leading litigator Torrey K. Young becomes new name partner at top New York trial boutique led by former federal prosecutor Marc L. Mukasey.
  • Mukasey Young will be ready to fight for clients who need to protect their freedom, their business or their reputation.

Jason Howard Launches New Catalyst Strategic Partners

Retrieved on: 
Tuesday, January 9, 2024
Professional Services, Finance, GCM, LP, Next Generation, APO, Partnership, Credit Suisse, Senior advisor, GP, Growth, Investment, LP record, Generation, TPG, GCM Grosvenor, Vista Equity Partners, Fine chemical

Jason Howard, an alternatives industry veteran known for investing in and advising General Partners (“GPs”), announced today the launch of New Catalyst Strategic Partners (“New Catalyst” or the “Firm”).

Key Points: 
  • Jason Howard, an alternatives industry veteran known for investing in and advising General Partners (“GPs”), announced today the launch of New Catalyst Strategic Partners (“New Catalyst” or the “Firm”).
  • Jason Howard, Founder and Managing Partner of New Catalyst Strategic Partners, said: “Even some of the most experienced investors face significant challenges when founding and growing new investment platforms, and these challenges can be even more pronounced for Next Generation GPs.
  • With the launch of New Catalyst, we will look to serve as the catalyst this industry needs.
  • I look forward to continuing and growing our strategic partnership.”
    Apollo is a founding supporter of New Catalyst and will continue to be a strategic partner to the Firm going forward.

Second Annual Analysis + Insights Report Takes Deep Dive into Public Safety

Retrieved on: 
Thursday, January 11, 2024
GIS, Model, Artificial intelligence, Next Generation, LMR, Failure, MCP, Analysis, Security, Geographic information system, AI, Ecosystem, Strategic planning, Chills, SME, Next, Organization, Land mobile radio system, Baby boomers, Annual report, News

STATE COLLEGE, Pa., Jan. 11, 2024 /PRNewswire-PRWeb/ -- Mission Critical Partners (MCP) announced the availability of its second edition Analysis + Insights Report, which examines a plethora of technological and operational challenges and opportunities that public safety agencies are facing today.

Key Points: 
  • Mission Critical Partners provides insights into the state of eight areas of the public safety market based on assessment data and anecdotal evidence.
  • STATE COLLEGE, Pa., Jan. 11, 2024 /PRNewswire-PRWeb/ -- Mission Critical Partners (MCP) announced the availability of its second edition Analysis + Insights Report, which examines a plethora of technological and operational challenges and opportunities that public safety agencies are facing today.
  • The report , which focuses on eight key factors, is based on MCP's proprietary assessment methodology known as the Model for Advancing Public Safety® (MAPS®).
  • MCP's subject-matter experts are uniquely positioned to provide this level of analysis, and we're already looking forward to producing the next annual report, because public safety's mission matters."

Global Next Generation Non Volatile Memory Industry Analysis Report 2023-2030 - High-Performance Computing (HPC) Offers Broad-based Opportunities for Market Growth

Retrieved on: 
Tuesday, January 9, 2024
Consumer, Growth, Next Generation, PCM, Tablet, Electronics, NVM, COVID-19, MRAM, Magnetoresistance, Ram

DUBLIN, Jan. 9, 2024 /PRNewswire/ -- The "Next Generation Non Volatile Memory - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 9, 2024 /PRNewswire/ -- The "Next Generation Non Volatile Memory - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The report also delves into the COVID-19 impact on the Next Generation Non-volatile Memory Market, shedding light on how the pandemic influenced this segment.
  • Global market analysis and prospects for next-generation non-volatile memory are discussed, highlighting the market's potential for burgeoning growth.
  • The Next Generation Non Volatile Memory market in the U.S. is estimated at US$2.1 Billion in the year 2022.

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH LILLY

Retrieved on: 
Sunday, January 7, 2024
Lilly, Dicarboxylic acid, Protein, Partnership, Drug discovery, Drug design, Biology, Isomorphic Labs, Eli Lilly and Company, AlphaFold, Next Generation, Intelligence, Therapy

LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company. This marks Isomorphic Labs' first pharmaceutical partnership.

Key Points: 
  • LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company.
  • Under the terms of the agreement, Isomorphic Labs will partner with Lilly to discover small molecule therapeutics against multiple targets and will receive an upfront cash payment of $45 million.
  • Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of AI to drug discovery.
  • Building on the success of AlphaFold and working in collaboration with Google DeepMind, Isomorphic Labs has made remarkable progress in developing the Next Generation of AlphaFold .

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH NOVARTIS

Retrieved on: 
Sunday, January 7, 2024
Dicarboxylic acid, Protein, Drug discovery, Research, Labs, Biology, Isomorphism, Biomedical Research, AI, Biomedicine, AlphaFold, Next Generation, Patient, Intelligence, Medicine, Therapy, Isomorphic Labs

LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets.

Key Points: 
  • "Isomorphic Labs and Novartis hold a shared purpose to reimagine medicine to improve and extend people's lives," said Demis Hassabis, CEO and founder of Isomorphic Labs.
  • Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of AI to drug discovery.
  • Building on the success of AlphaFold and working in collaboration with GoogleDeepMind, Isomorphic Labs has made remarkable progress in developing the Next Generation of AlphaFold .
  • Under the terms of the agreement, Isomorphic Labs will receive an upfront payment of $37.5 million from Novartis, in addition to Novartis funding of select research costs.

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH LILLY

Retrieved on: 
Sunday, January 7, 2024
Lilly, Dicarboxylic acid, Protein, Partnership, Drug discovery, Drug design, Biology, Isomorphic Labs, Eli Lilly and Company, AlphaFold, Next Generation, Intelligence, Therapy

LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company. This marks Isomorphic Labs' first pharmaceutical partnership.

Key Points: 
  • LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company.
  • Under the terms of the agreement, Isomorphic Labs will partner with Lilly to discover small molecule therapeutics against multiple targets and will receive an upfront cash payment of $45 million.
  • Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of AI to drug discovery.
  • Building on the success of AlphaFold and working in collaboration with Google DeepMind, Isomorphic Labs has made remarkable progress in developing the Next Generation of AlphaFold .

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH NOVARTIS

Retrieved on: 
Sunday, January 7, 2024
Dicarboxylic acid, Protein, Drug discovery, Research, Labs, Biology, Isomorphism, Biomedical Research, AI, Biomedicine, AlphaFold, Next Generation, Patient, Intelligence, Medicine, Therapy, Isomorphic Labs

LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets.

Key Points: 
  • "Isomorphic Labs and Novartis hold a shared purpose to reimagine medicine to improve and extend people's lives," said Demis Hassabis, CEO and founder of Isomorphic Labs.
  • Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of AI to drug discovery.
  • Building on the success of AlphaFold and working in collaboration with GoogleDeepMind, Isomorphic Labs has made remarkable progress in developing the Next Generation of AlphaFold .
  • Under the terms of the agreement, Isomorphic Labs will receive an upfront payment of $37.5 million from Novartis, in addition to Novartis funding of select research costs.